Conditions: Metabolic Diseases Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders
Keywords: Glucose Insulin
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 69
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the effects of mineralocorticoid receptor (MR) antagonism and renin inhibition on glucose metabolism in humans.

Detailed description:
The purpose of this study is to determine the effects of mineralocorticoid receptor (MR) antagonism and renin inhibition on fasting blood glucose and glucose-stimulated insulin secretion in humans.

Arms:
arm 1: Hydrochlorothiazide (HCTZ) 12.5mg daily for 1 month

then HCTZ 12.5mg daily plus Aliskiren 150 mg (ALI 150) daily for 1 month

then HCTZ 12.5mg daily plus Aliskiren 300mg ((ALI 300) for 1 month arm 2: HCTZ 12.5mg daily for 1 month

then HCTZ 12.5mg daily plus Aliskiren 150 mg daily for 1 month

then HCTZ 12.5mg daily plus Aliskiren 150 mg daily and Spironolactone 25mg (SPL 25) daily for one month arm 3: HCTZ 12.5mg daily for 1 month

then HCTZ 12.5mg daily plus Spironolactone 25 mg (SPL 25) daily for 1 month

then HCTZ 12.5mg daily plus Spironolactone 50 mg daily for one month arm 4: HCTZ 12.5mg daily for 1 month

then HCTZ 12.5mg daily plus Spironolactone 25 mg daily for 1 month

then HCTZ 12.5mg daily plus Aliskiren 150 mg daily and Spironolactone 25 mg daily for one month

Interventions: intervention 1: Hydrochlorothiazide (HCTZ) intervention 2: Aliskiren 150 mg (ALI 150) intervention 3: Spironolactone (SPL 25) intervention 4: Aliskiren 300 mg (ALI 300) intervention 5: Spironolactone 50 mg (SPL 50)
Intervention descriptions: intervention 1: HCTZ 12.5mg daily intervention 2: Aliskiren 150mg daily intervention 3: spironolactone 25mg daily intervention 4: Aliskiren 300mg daily intervention 5: Spironolactone 50 mg daily

Protocol document: